|
1
|
DeLellis RA, Lloyd RV, Heitz PU and Eng C:
Papillary carcinomaWorld health organization classifications of
tumours: Pathology and genetics of tumours of endocrine organs.
IARC Press; Lyon: pp. 57–66. 2004
|
|
2
|
Toniato A, Boshin I, Casara D, Mazzarotto
R, Rubello D and Pelizzo M: Papillary thyroid carcinoma: Factors
influencing recurrence and survival. Ann Surg Oncol. 15:1518–1522.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Spriano G, Ruscito P, Pellini R,
Appetecchia M and Roselli R: Pattern of regional metastases and
prognostic factors in differentiated thyroid carcinoma. Acta
Otorhinolaryngol Ital. 29:312–316. 2009.PubMed/NCBI
|
|
4
|
Ito Y and Miyauchi A: Prognostic factors
and therapeutic strategies for differentiated carcinoma of the
thyroid. Endocr J. 56:177–192. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jung TS, Kim TY, Kim KW, Oh YL, Park DJ,
Cho BY, Shong YK, Kim WB, Park YJ, Jung JH and Chung JH: Clinical
features and prognostic factors for survival in patients with
poorly differentiated thyroid carcinoma and comparison to the
patients with the aggressive variants of papillary thyroid
carcinoma. Endocr J. 54:265–274. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yoshida BA, Skoloff MM, Welch DR and
Rinker-Schaeffer CW: Metastasis-supressor genes: A review and
perspective on an emerging field. J Natl Cancer Inst. 92:1717–1730.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rosengard AM, Krutzsch HC, Shearn A, Biggs
JR, Barker E, Marguilies IM, King CR, Liotta LA and Steeg PS:
Reduced Nm23/Awd protein in tumour metastasis and aberrant
Drosphila development. Nature. 342:177–180. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lacombe ML, Milon L, Munier A, Mehus JG
and Lambeth DO: The human Nm23/nucleoside diphosphate kinases. J
Bioenerg Biomembr. 32:247–258. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ouatas T, Salerno M, Palmieri D and Steeg
PS: Basic and translational advances in cancer metastasis: Nm23. J
Bioenerg Biomembr. 35:73–79. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee JH, Marshall JC, Steeg PS and Horak
CE: Altered gene and protein expression by Nm23-H1 in metastasis
suppression. Mol Cell Biochem. 329:141–148. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zou M, Shi Y, Al-Sedairy S and Farid NR:
High levels of Nm23 gene expression in advanced stage of thyroid
carcinomas. Br J Cancer. 68:385–388. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ferenc T, Lewiński A, Lange D,
Niewiadomska H, Sygut J, Sporny S, Włoch J, Sałacińska-Los E, Kulig
A and Jarzab B: Analysis of Nm23-H1 protein immunoreactivity in
follicular thyroid tumors. Pol J Pathol. 55:149–153.
2004.PubMed/NCBI
|
|
13
|
Luo W, Matsuo K, Nagayama Y, Urano T,
Furukawa K, Takeshita A, Nakayama T, Yokoyama N, Yamashita S and
Izumi M: Immunohistochemical analysis of expression of
nm23-H1/nucleoside diphosphate kinase in human thyroid carcinomas:
Lack of correlation between its expression and lymph node
metastasis. Thyroid. 3:105–109. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Farley DR, Eberhardt NL, Grant CS, Schaid
DJ, van Heerden JA, Hay ID and Khosla S: Expression of a potential
metastasis suppressor gene (nm23) in thyroid neoplasms. World J
Surg. 17:615–621. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Royds JA, Silcocks PB, Rees RC and
Stephenson TJ: Nm23 protein expression in thyroid neoplasms.
Pathologica. 86:240–243. 1994.PubMed/NCBI
|
|
16
|
Tabriz HM, Adabi Kh, Lashkari A, Heshmat
R, Haghpanah V, Larijani B and Tavangar SM: Immunohistochemical
analysis of nm23 protein expression in thyroid papillary carcinoma
and follicular neoplasm. Pathol Res Pract. 205:83–87. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shahebrahimi K, Madani SH, Fazaeli AR,
Khazaei S, Kanani M and Keshavarz A: Diagnostic value of CD56 and
nm23 markers in papillary thyroid carcinoma. Indian J Pathol
Microbiol. 56:2–5. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Maud JF, Alfin-Slater RB, Howton DR and
Popjak G: Prostaglandins, tromboxanes and prostacyclinLipids:
Chemistry, Biochemistry, and Nutrition. Springer US; New York, NY:
pp. 149–216. 1986, View Article : Google Scholar
|
|
19
|
Crofford LJ: COX-1 and COX-2 tissue
expression: Implications and predictions. J Rheumatol Suppl.
49:15–19. 1997.PubMed/NCBI
|
|
20
|
NCBI Gene: PTGS1
prostaglandin-endoperoxide synthase 1 [Homo sapiens
(human)]. GENE ID: 5742. updated on 20-Feb-2017. https://www.ncbi.nlm.nih.gov/gene/5742
|
|
21
|
NCBI Gene: PTGS2
prostaglandin-endoperoxide synthase 2 [Homo sapiens
(human)]. GENE ID: 5743. updated on 26-Feb-2017. https://www.ncbi.nlm.nih.gov/gene/5743
|
|
22
|
Dubois RN, Abramson SB, Crofford L, Gupta
RA, Simon LS, van de Putte LB and Lipsky PE: Cyclooxygenase in
biology and disease. FASEB J. 12:1063–1073. 1998.PubMed/NCBI
|
|
23
|
Vane JR, Bakhle YS and Botting RM:
Cyclooxigenases 1 and 2. Annu Rev Pharmacol Toxicol. 38:97–120.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Specht MC, Tucker ON, Hocever M, Gonzalez
D, Teng L and Fahey TJ III: Cyclooxygenase-2 expression in thyroid
nodules. J Clin Endocronol Metab. 87:358–363. 2002. View Article : Google Scholar
|
|
25
|
Ji B, Liu Y, Zhang P, Wang Y and Wang G:
COX-2 expression and tumor angiogenesis in thyroid carcinoma
patients among northeast Chinese population-result of a
single-center study. Int J Med Sci. 9:237–242. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Krawczyk-Rusiecka K,
Wojciechowska-Durczynska K, Cyniak-Magierska A, Zygmunt A and
Lewinski A: Assessment of cyclooxygenase-1 and 2 gene expression
levels in chronic autoimmune thyroiditis, papillary thyroid
carcinoma and nontoxic nodular goitre. Thyroid Res. 7:102014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Siironen P, Ristimäki A, Nordling S,
Louhimo J, Haapiainen R and Haglund C: Expression of Cox-2 is
increased with age in papilary thyroid cancer. Histopathology.
44:490–497. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim SJ, Lee J, Yoon JS, Mok JO, Kim YJ,
Park HK, Kim CH, Byun DW, Suh KI and Yoo MH: Immunohistochemical
expression of COX-2 in thyroid nodules. Korean J Int Med.
18:225–229. 2003. View Article : Google Scholar
|
|
29
|
Ito Y, Yoshida H, Naakano K, Takamura Y,
Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Matsuura N, Kuma K
and Miyauchi A: Cyclooxygenase-2 expression in thyroid neoplasms.
Histopathology. 42:492–497. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim YA, Chang M, Park YJ and Kim JE:
Detection of survivin and COX-2 in thyroid carcinoma: Anaplastic
carcinoma shows overexpression of nuclear surviving and low COX-2
expression. Korean J Pathol. 46:55–60. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Scarpino S, Duranti E, Giglio S, Di Napoli
A, Galafate D, Del Bufalo D, Desideri M, Socciarelli F,
Stoppacciaro A and Ruco L: Papillary carcinoma of the thyroid: High
expression of COX-2 and low expression of KAI-1/CD82 are associated
with increased tumor invasiveness. Thyroid. 23:1127–1137. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cornetta AJ, Russell JP, Cunnane M, Keane
WM and Rothstein JL: Cyclooxygenase-2 expression in human thyroid
carcinoma and Hashimoto's thyroiditis. Laryngoscope. 11:238–242.
2002. View Article : Google Scholar
|
|
33
|
Nose F, Ichikawa T, Fujiwara M and Okayasu
I: Up-regulation of cyclooxygenase-2 expression in lymphocytic
thyroiditis and thyroid tumors: Significant correlation with
inducible nitric oxide synthase. Am J Clin Pathol. 117:546–551.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kaul R, Verma SC, Murakami M, Lan K,
Choudhuri T and Robertson ES: Epstein-Barr virus protein can
upregulate cyclo-oxygenase-2 expression through association with
the supressor of metastasis Nm23-H1. J Virol. 80:1321–1331. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Joo YE, Kim HS, Min SW, Lee WS, Park CH,
Park CS, Choi SK, Rew JS and Kim SJ: Expression of cyclooxigenase-2
protein in colorectal carcinomas. Int J Gastrointest Cancer.
31:147–154. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Soslow RA, Dannenberg AJ, Rush D, Woerner
BM, Khan KN, Masferrer J and Koki AT: COX-2 is expressed in human
pulmonary, colonic, and mammary tumors. Cancer. 89:2637–2645. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Barnes R, Masood S, Barker E, Rosengard
AM, Coggin DL, Crowell T, King CR, Porter-Jordan K, Wargotz ES and
Liotta LA: Low nm23 protein expression in infiltrating ductal
breast carcinomas correlates with reduced patient survival. Am J
Pathol. 139:245–250. 1991.PubMed/NCBI
|
|
38
|
Yamaguchi A, Ding K, Maehara M, Goi T and
Nakagawara G: Expression of nm23-H1 gene and Sialyl Lewis × antigen
in breast cancer. Oncology. 55:357–362. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Russell JP, Shinohara S, Melillo RM,
Castellone MD, Santoro M and Rothstein JL: Tyrosine kinase
oncoprotein, RET/PTC3, induces the secretion of myeloid growth and
chemotactic factors. Oncogene. 22:4569–4577. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Erdem H, Gündogdu C and Şipal S:
Correlation of E-cadherin, VEGF, COX-2 expression to prognostic
parameters in papillary thyroid carcinoma. Exp Mol Pathol.
90:312–317. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
García-González M, Abdulkader I, Boquete
AV, Neo XM, Forteza J and Cameselle-Teijeiro J: Cyclooxigenase-2 in
normal, hyperplastic and neoplastic follicular cells of the human
thyroid gland. Virchows Arch. 447:12–17. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Eschwège P, de Ledinghen V, Camilli T,
Kulkarni S, Dalbagni G, Droupy S, Jardin A, Benoît G and Weksler
BB: Arachidonic acid and prostaglandins, inflammation and oncology.
Presse Med. 30:508–510. 2001.(In French). PubMed/NCBI
|
